Date Subject Details
2024/07/04 Taiwan MOHW has approved the collaborativeautologous Gamma-Delta T cell therapy project bythe Company and TaipeiMunicipal Wanfang Hospital 20240704
2024/06/06 Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Wanfang Hospital 20240606
2024/06/03 The first participant has been enrolled in the investigator-initiated Phase II clinical trial of the new drug OBP-301 in the United States. 20240603
2024/05/28 Announcement of the Members of the Company’ssixth term of Remuneration Committee 20240528-6
2024/05/28 Announcement of the Members of the Company’ssecond term of Audit Committee 20240528-5
2024/05/28 Announcement of the Election of the Chairmanof the Board of Directors 20240528-4
2024/05/28 Approval of the Proposal to Lift the Non-CompeteRestrictions on Newly Appointed Directors at 2024Shareholders’ Meeting. 20240528-3
2024/05/28 Announcement of the Newly Elected Board of Directors(including Independent Directors) at the 2024 AnnualShareholders’ Meeting of the Company 20240528-2
2024/05/28 Announcement of Important Resolutions fromthe 2024 Shareholders’ Meeting of the Company 20240528-1
2024/05/10 The Company’s 2024Q1 consolidated financial statements have been approved by the Board of Directors 20240510
2024/05/02 Announcement of the date of the board ofdirectors meeting for the first quarter of 2024financial report 20240502
2024/04/23 Taiwan MOHW has approved a new version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Hualien Tzu Chi Hospital 20240423
2024/04/10 Announcement Completion of Cancellation of NewlyIssued Restricted Employee Shares and Relevant Changesin Registration 20240410
2024/03/29 The Ministry of Health and Welfare has approvedthe collaborative autologous Gamma-Delta T cell therapyproject by the Company and Chi Mei Hospital, Liouying 20240329
2024/03/26 Taiwan MOHW has approved a new version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Changhua Christian Hospital 20240326
2024/03/20 Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Chi Mei Hospital, Liouying 20240320
2024/03/12 Announcement to explain the difference between thecompany’s consolidated monthly operating incomedeclaration for 12/2024 and accountants audited numbers. 20240312
2024/03/11 Announcement to explain the difference between thecompany’s consolidated monthly operating incomedeclaration for 12/2024 and accountants audited numbers. 20240311-6
2024/03/11 The Board of Directors has resolved not to distributedividends 20240311-5
2024/03/11 The Company’s board of directors resolvedto convene 2024 General Shareholder’s meeting 20240311-4
2024/03/11 Appointment of our company’s new ChiefScientific Officer 20240311-3
2024/03/11 The Company’s Board of Directors has resolvedto redeem and cancel the restricted stocks issued toemployees 20240311-2
2024/03/11 The Company’s 2023 consolidated financialstatements have been approved by the Board of Directors 20240311-1
2024/02/29 Our company has applied to the Taiwan Food and DrugAdministration (TFDA) for Phase I/II clinical trial ofallogeneic natural killer cells (Magicell-NK) 20240229
2024/02/16 The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Changhua Christian Hospital 20240216
2024/02/07 Signing of the sales cooperation agreementfor the new drug OBP-301 in Japan. 20240207
2024/01/30 Announcement of Important Resolutions by the Board of Directors of Our Company 20240130
2024/01/11 Approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Taichung Tzu Chi Hospital 20240111